Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer

Current Oncology

Volumn 21, Issue 4, 2014, Pages

  Ewara, E M ^a   Zaric, G S ^a,b   Welch, S ^c   Sarma, Sisira ^a  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Bevacizumab; Cetuximab; Cost effectiveness; Folfiri; Metastatic colorectal cancer; Ontario; Panitumumab; Wild type KRAS

Indexed keywords

EID: 84905693713     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1837     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. [Erratum in: CA Cancer J Clin 2011;61:134]
2. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2012. Toronto, O N: Canadian Cancer Society; 2012. [Available online at: https://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2012---English.pdf; cited September 9, 2013]
3. Van Cutsem E, Nordlinger B, Adam R, et al. on behalf of the European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006;42:2212-21.
4. Colucci G, Gebbia V, Paoletti G, et al. Phase iii randomized trial of folfiri versus folfox4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-75.
5. Tournigand C, Andre T, Achille E, et al. folfiri followed by folfox6 or the reverse sequence in advanced colorectal cancer: a randomized gercor study. J Clin Oncol 2004;22:229-37.
6. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006;24:3347-53.
7. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19.
8. Sobrero A, Ackland S, Clarke S, et al. on behalf of the aviri Trial investigators. Phase iv study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (folfiri) in first-line metastatic colorectal cancer. Oncology 2009;77:113-19. [Erratum in: Oncology 2009;77:256]
9. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the bicc-c Study. J Clin Oncol 2007;25:4779-86.
10. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
11. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (brite). J Clin Oncol 2008;26:5326-34.
12. Welch S, Spithoff K, Rumble RB, Maroun J on behalf of the Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 2010;21:1152-62.
13. Dranitsaris G, Edwards S, Edwards J, Leblanc M, Abbott R. Bevacizumab in combination with folfiri chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador. Curr Oncol 2010;17:12-16.
14. Vincent M, Craven J. Use of Bevacizumab in Advanced Colorectal Cancer: GI Practice Guideline. London, ON: London Health Sciences Centre; 2007.
15. Strother JM, CD Blanke. Integration of antiangiogenic strategies into colorectal cancer treatment. In: Saltz LB, ed. Colorectal Cancer: Evidence-Based Chemotherapy Strategies. Totowa, NJ: Humana Press; 2007: 85-98.
16. United States, Department of Health and Human Services, Food and Drug Administration (fda). FDA approves first angiogenesis inhibitor to treat colorectal cancer [news release]. Silver Spring, MD: fda; 2004. [Available online at: http://www.fda.gov/newsevents/newsroom/pressannouncements/2004/ucm108252.htm; cited September 9, 2013]
17. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009;27:1130-6.
18. Lin JK, Lin AJ, Lin CC, et al. The status of egfr-associated genes could predict the outcome and tumor response of chemorefractory metastatic colorectal patients using cetuximab and chemotherapy. J Surg Oncol 2011;104:661-6.
19. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-19.
20. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase iii trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the prime study. J Clin Oncol 2010;28:4697-705.
21. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64.
22. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics 2007;25:3-6.
23. Ishak KJ, Kreif N, Benedict A, Muszbek N. Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics 2013;31:663-75.
24. Statistics Canada. Complete life table, Ontario, 2000 to 2002 [Web resource]. Ottawa, ON: Statistics Canada; 2006. [Files available for download at: http://www.statcan.gc.ca/pub/84-537-x/4064441-eng.htm; cited June 12, 2014]
25. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000;88:1294-303.
26. Whyte S, Pandor A, Stevenson M, Rees A. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. Health Technol Assess 2010;14(suppl 2):47-53.
27. Bennett L, Zhao Z, Barber B, et al. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Br J Cancer 2011;105:1495-502.
28. Odom D, Barber B, Bennett L, et al. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis 2011;26:173-81.
29. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with folfox, xelox, folfiri and fluoropyrimidines in metastatic colorectal cancer: the beat study. Ann Oncol 2009;20:1842-7.
30. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10- year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25:4575-80.
31. Asseburg C, Frank M, Kohne CH, et al. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wildtype colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther 2011;33:482-97.
32. Samyshkin Y, Hertel N, Griebsch I. Cost-effectiveness of cetuximab, bevacizumab, and panitumumab in first-line treatment of metastatic colorectal cancer (mcrc) for patients with KRAS wild-type (wt) tumors in the United Kingdom [abstract e16571]. J Clin Oncol 2011;29:. [Available online at: http://meetinglibrary.asco.org/content/81476-102; cited May 22, 2014]
33. Heinemann V, Fischer von Weikersthal L, Decker T, et al. Randomized comparison of folfiri plus cetuximab versus folfiri plus bevacizumab as first-line treatment of KRAS wildtype metastatic colorectal cancer: German aio study krk-0306 (fire-3) [abstract LBA3506]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary.asco.org/content/110092-132; cited May 22, 2014]